Adaptimmune Therapeutics
ADAP
#9324
Rank
โ‚ฌ60.56 M
Marketcap
0,24ย โ‚ฌ
Share price
-20.31%
Change (1 day)
-81.36%
Change (1 year)

Revenue for Adaptimmune Therapeutics (ADAP)

Revenue in 2024 (TTM): โ‚ฌ0.16 Billion

According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is โ‚ฌ0.16 Billion. an increase over the revenue in the year 2023 that were of โ‚ฌ54.53 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Adaptimmune Therapeutics from 2016 to 2024

Annual revenue

Year Revenue Change
2024 โ‚ฌ0.17 B213.74%
2023 โ‚ฌ54.53 M115.46%
2022 โ‚ฌ25.3 M366.13%
2021 โ‚ฌ5.42 M68.73%
2020 โ‚ฌ3.21 M221.28%
2019 โ‚ฌ1 M-98.07%
2018 โ‚ฌ52.01 M64.96%
2017 โ‚ฌ31.53 M133.6%
2016 โ‚ฌ13.49 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ0.62 B 283.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ26.54 M-83.66%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ20.69 M-87.26%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
โ‚ฌ1.97 B 1,118.15%๐Ÿ‡บ๐Ÿ‡ธ USA